Literature DB >> 33264413

Manganese Porphyrin and Radiotherapy Improves Local Tumor Response and Overall Survival in Orthotopic Murine Mammary Carcinoma Models.

Mary-Keara Boss1, Rebecca E Oberley-Deegan2, Ines Batinic-Haberle3, Geoffrey A Talmon4, Jason A Somarelli5, Shengnan Xu5, Elizabeth A Kosmacek2, Brandon Griess2, Shakeel Mir2, Shashank Shrishrimal2, Melissa Teoh-Fitzgerald2, Ivan Spasojevic5, Mark W Dewhirst3.   

Abstract

Novel synthetic compounds, known as manganese porphyrins (MnPs), have been designed to shift the redox status of both normal cells and cancer cells. When MnPs are coupled with cancer therapies, such as radiation, they have been shown to sensitize tumor cells to treatment and protect normal tissues from damage through the modulation of the redox status of various tissue types. Until now, our preclinical studies have focused on local effects of MnPs and radiation; however, we recognize that successful outcomes for cancer patients involve control of tumor cells throughout the body. In this study, using murine orthotopic mammary tumor models, we investigated how MnPs and radiation influence the development of distant metastasis. We hypothesized that the combination of MnP (MnP/RT), such as MnTnBuOE-2-PyP5+ and radiation treatment (RT) would increase local tumor control via a shift in the intratumoral redox environment, leading to subsequent downregulation of HIF-1 in the primary tumor. Secondarily, we hypothesized that these primary tumor treatment effects would result in a reduction in pulmonary metastatic burden. Balb/c mice with orthotopic 4T1 mammary carcinomas were treated with saline, MnP, RT or MnP/RT. We found MnP/RT did extend local tumor growth delay and overall survival compared to controls and was associated with increased intratumoral oxidative stress. However, the primary tumor growth delay observed with MnP/RT was not associated with a reduced pulmonary metastatic burden. Future directions to investigate the effects of MnP/RT on the development of distant metastasis may include modifications to the radiation dose, the experimental timeline or using a murine mammary carcinoma cell line with a less aggressive metastatic behavior. Clinical trials are underway to investigate the clinical utility of MnTnBuOE-2-PyP5+ for patients undergoing radiotherapy for various tumor types. The promising preclinical data from this study, as well as others, provides support that MnP/RT has the potential to improve local tumor control for these patients. ©2021 by Radiation Research Society. All rights of reproduction in any form reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33264413      PMCID: PMC7962472          DOI: 10.1667/RADE-20-00109.1

Source DB:  PubMed          Journal:  Radiat Res        ISSN: 0033-7587            Impact factor:   2.841


  44 in total

Review 1.  Free radicals, metals and antioxidants in oxidative stress-induced cancer.

Authors:  M Valko; C J Rhodes; J Moncol; M Izakovic; M Mazur
Journal:  Chem Biol Interact       Date:  2006-01-23       Impact factor: 5.192

2.  Mechanism of the Antitumor and Radiosensitizing Effects of a Manganese Porphyrin, MnHex-2-PyP.

Authors:  Sung-Won Shin; Changhoon Choi; Ga-Haeng Lee; Arang Son; Su-Hyeon Kim; Hee Chul Park; Ines Batinic-Haberle; Won Park
Journal:  Antioxid Redox Signal       Date:  2017-03-30       Impact factor: 8.401

3.  Phase III randomized trial of amifostine as a radioprotector in head and neck cancer.

Authors:  D M Brizel; T H Wasserman; M Henke; V Strnad; V Rudat; A Monnier; F Eschwege; J Zhang; L Russell; W Oster; R Sauer
Journal:  J Clin Oncol       Date:  2000-10-01       Impact factor: 44.544

4.  Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer.

Authors:  Toru Hiraga; Shinae Kizaka-Kondoh; Kiichi Hirota; Masahiro Hiraoka; Toshiyuki Yoneda
Journal:  Cancer Res       Date:  2007-05-01       Impact factor: 12.701

5.  Integrin-linked kinase regulates osteopontin-dependent MMP-2 and uPA expression to convey metastatic function in murine mammary epithelial cancer cells.

Authors:  Zhiyong Mi; Hongtao Guo; Philip Y Wai; Chengjiang Gao; Paul C Kuo
Journal:  Carcinogenesis       Date:  2006-02-12       Impact factor: 4.944

6.  HIF1α and HIF2α independently activate SRC to promote melanoma metastases.

Authors:  Sara C Hanna; Bhavani Krishnan; Sean T Bailey; Stergios J Moschos; Pei-Fen Kuan; Takeshi Shimamura; Lukas D Osborne; Marni B Siegel; Lyn M Duncan; E Tim O'Brien; Richard Superfine; C Ryan Miller; M Celeste Simon; Kwok-Kin Wong; William Y Kim
Journal:  J Clin Invest       Date:  2013-04-08       Impact factor: 14.808

7.  Comparison of two Mn porphyrin-based mimics of superoxide dismutase in pulmonary radioprotection.

Authors:  Benjamin Gauter-Fleckenstein; Katharina Fleckenstein; Kouros Owzar; Chen Jiang; Ines Batinic-Haberle; Zeljko Vujaskovic
Journal:  Free Radic Biol Med       Date:  2007-11-21       Impact factor: 7.376

8.  Clinicopathological characteristics of gynecological cancer associated with hypoxia-inducible factor 1α expression: a meta-analysis including 6,612 subjects.

Authors:  Yue Jin; Haolu Wang; Xiaowei Ma; Xiaowen Liang; Xin Liu; Yu Wang
Journal:  PLoS One       Date:  2015-05-19       Impact factor: 3.240

9.  Rational design of superoxide dismutase (SOD) mimics: the evaluation of the therapeutic potential of new cationic Mn porphyrins with linear and cyclic substituents.

Authors:  Artak Tovmasyan; Sebastian Carballal; Robert Ghazaryan; Lida Melikyan; Tin Weitner; Clarissa G C Maia; Julio S Reboucas; Rafael Radi; Ivan Spasojevic; Ludmil Benov; Ines Batinic-Haberle
Journal:  Inorg Chem       Date:  2014-10-21       Impact factor: 5.165

10.  The Addition of Manganese Porphyrins during Radiation Inhibits Prostate Cancer Growth and Simultaneously Protects Normal Prostate Tissue from Radiation Damage.

Authors:  Arpita Chatterjee; Yuxiang Zhu; Qiang Tong; Elizabeth A Kosmacek; Eliezer Z Lichter; Rebecca E Oberley-Deegan
Journal:  Antioxidants (Basel)       Date:  2018-01-25
View more
  2 in total

1.  A Redox-active Mn Porphyrin, MnTnBuOE-2-PyP5+, Synergizes with Carboplatin in Treatment of Chemoresistant Ovarian Cell Line.

Authors:  Luksana Chaiswing; Chontida Yarana; William St Clair; Artak Tovmasyan; Ines Batinic-Haberle; Ivan Spasojevic; Daret St Clair
Journal:  Oxid Med Cell Longev       Date:  2022-05-09       Impact factor: 7.310

2.  Exploiting DNA repair pathways for tumor sensitization, mitigation of resistance, and normal tissue protection in radiotherapy.

Authors:  Jac A Nickoloff; Lynn Taylor; Neelam Sharma; Takamitsu A Kato
Journal:  Cancer Drug Resist       Date:  2021-06-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.